An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children.
(2002) The Journal of Infectious Diseases — Vol. 186 Suppl 1, p. S123-S130 (2002)
Files
pdfdocument.pdf
Restricted Access - Adobe PDF
- 1.43 MB
Details
- Authors
- Abstract
- Valacyclovir was administered to 28 immunocompromised children (ages 5-12 years) to obtain preliminary pharmacokinetic and safety information. Patients were randomized to valacyclovir regimens of 250 mg (9.4-13.3 mg/kg) or 500 mg (13.9-27.0 mg/kg) twice daily or 500 mg (13.2-21.7 mg/kg) 3 times a day. Acyclovir pharmacokinetics were evaluated at steady state. Valacyclovir was rapidly absorbed and converted to acyclovir. Mean (+/-SD) acyclovir peak concentrations from 250 mg and 500 mg valacyclovir were 4.11+/-1.41 and 5.19+/-1.96 microg/mL, respectively. Corresponding single dose area-under-curve values were 12.14+/-6.60 and 14.49+/-4.69h microg/mL. By using historical data for intravenous acyclovir as reference, the overall estimate of acyclovir bioavailability from valacyclovir was 48%, 2- to 4-fold greater than for oral acyclovir. In general, adverse events were not attributable to valacyclovir and were consistent with disease-related expectations and concomitant therapies. Dosage options for using valacyclovir in children are discussed.
- Affiliations
Citations
Nadal, D., Leverger, G., Sokal, E., Floret, D., Perel, Y., Leibundgut, K., & Weller, S. (2002). An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children. The Journal of Infectious Diseases, 186 Suppl 1, S123-S130. https://doi.org/10.1086/342968 (Original work published 2002)